December 20, 2022
Resmetirom Reduces Liver, CV Risk Factors in NASH With Cirrhosis
WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and effective at lowering markers of both cardiovascular risk and NASH fibrosis, new research has found. Two cohorts comprising a total of 180 patients with well-compensated NASH cirrhosis enrolled in […]